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Pharmacologically active: clinical trials and the 
pharmaceutical industry
Michael Kahn, Michael Gastrow
The South African pharmaceutical 
industry
The South African Government’s Department of Health (DOH), 
through the Medicines Control Council (MCC), licenses 75 
companies to manufacture pharmaceuticals, 24 to carry out 
quality control and testing, and 251 to function as importers, 
wholesalers or retailers of products.2 The MCC also issues 
licences for the performance of clinical trials. Multinational 
pharmas dominate the local industry, and 7 of them have local 
production plants. The South African pharmaceutical industry 
turnover is estimated at around R14.1 billion, including imports 
of R7.44 billion and exports3 of approximately R0.77 billion. 
Measuring pharmaceutical R&D in South Africa
There is no reliable published value of pharmaceutical 
industry expenditure on clinical trials. The Pharmaceutical 
Manufacturers Association, on the basis of a survey of its 
members, estimated that the 2004 spend was in the order of 
R650 million (personal communication with Maureen Kirkman, 
Head: Scientific and Regulatory Affairs, Pharmaceutical 
Industry Association of South Africa), but it is unclear whether 
this included phase IV trials as well. Their current estimate is 
in the order of R900 million. 
The Organisation for Economic Co-operation and 
Development (OECD) survey guidelines for R&D state that: 
‘Clinical trial phases I, II and III can be treated as R&D. Phase 
IV clinical trials, which continue testing the drug or treatment 
after approval and manufacture, should only be treated as 
R&D if they bring about a further scientific or technological 
advance’.4 
To determine the scale of current pharmaceutical R&D and 
clinical trials, three sources of data are used: the South African 
National Clinical Trials Register (SANCTR);2 United States 
National Institutes of Health website;5 and national R&D 
surveys that are official statistics under the Statistics Act No. 6 
of 1999.
The SANCTR lists 308 active trials by condition without 
declaring their phase. A contact person with a telephone 
number is listed, but extensive inquiry yielded almost no 
further information save a few responses indicating phase 
III activities. One cannot readily distinguish industry from 
university or private clinical trials from this information.
The US database, on the other hand, clearly identifies 172 
active industry-sponsored trials in South Africa. Another 
53 trials are mainly supported by non-industry sources. 
Unfortunately, neither database provides enrolment per 
country that could be used to estimate the cost associated with 
each clinical trial.
The annual National R&D Survey continually updates its 
register of pharmaceutical R&D performers by direct enquiry, 
studying the media, and annual reports of listed companies.
Findings
The 2005/2006 R&D Survey (Table I) shows excellent 
overlap with the US company data and recorded 28 firms 
(22 ‘manufacturers’ and 6 ‘contract research organisations’ or 
CROs) with expenditure on R&D (including clinical trials) of 
some R822 million.
While the 2005/2006 level of pharmaceutical-related R&D 
represents a 3% real growth from 2004/2005, it represents a 
slight decline from 11.8% down to 10.2% in relation to total 
business expenditure on R&D.
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Multinational pharmaceutical companies (‘pharmas’) import 
and produce pharmaceuticals and also conduct clinical trials 
which are an important aspect of research and development 
(R&D). This may raise the question: Is South Africa a guinea 
pig for the pharmas? The Department of Trade and Industry 
National Industrial Policy Framework1 designates chemicals, 
plastic fabrication and pharmaceuticals as a key value 
chain. So a second question could be: Can South Africa be a 
manufacturer for the pharmas, or can it leverage strengths 
in medical research and the conducting of clinical trials so 
as to develop a discovery-led industry? This paper analyses 
and quantifies the state of the clinical trials industry in South 
Africa, and concludes that: (i) a sizeable clinical trials industry 
exists, and that these trials are predominantly phase 3 and 
global in scope; (ii) South Africa is not a specific or unique 
guinea pig – a range of conditions is studied as part of global 
trials; and (iii) while South Africa has excellent prospects for 
increased clinical trials activity, R&D investment is too low to 
make it a major pharmaceutical contender. 
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Capital expenditure related to R&D is a good indicator 
of laboratory investment and experimentation. Of the 
‘manufacturers’, only two showed any capital expenditure on 
R&D, amounting to R119 million, or 14.3%, of the 2005/2006 
total. On the other hand, the median R&D-related capital 
expenditure for the 28 firms is about R1.5 million – an 
extremely low amount, from which it may be concluded 
that, by and large, the firms are engaged only in routine 
pharmaceutical manufacturing, and in the management and 
conducting of clinical trials.
The firms report R0.3 million of government funding, 
and R402 million in internal and domestic business sector 
funding, compared with an inward flow of foreign funds to 
themselves of R420 million (Table II). These figures highlight 
that government plays little role in funding business sector 
pharmaceutical R&D, although the National Industrial Policy 
Framework may change this.
The ratio of the cost of labour to current expenditure for 
firms in the pharmaceutical sector shows a marked deviation 
from the 1:1 norm for the business sector. The former ratio, at 
2:1, suggests significant unspecified labour costs. This reflects 
one of the main challenges in measuring clinical trials R&D: 
underestimation of the headcount of researchers who are 
operating within extended clinical trials R&D value chains. 
Companies often do not have a direct way of reporting these 
headcount data. Accordingly, the 491 full-time equivalent 
researchers recorded in the pharmaceutical sector is a lower 
bound and might be less than one half of the researcher 
workforce involved in clinical trials outside the public sector. 
This figure should be seen in the context of the 3 700 specialists 
and 12 000 GPs in the country. 
Most trials in which South Africa is one of many 
participating countries, are global (149), where ‘global’ is 
defined as encompassing more than five countries (Table III), 
as opposed to multinational trials which include South Africa 
and up to four other countries (19) or those where South Africa 
is a unique country, which occurs only 4 times. Of the 172 
clinical trials, 40 concentrate on cardiovascular conditions, 23 
on cancers and 21 on diabetes. The remaining 88 trials cover 
another 20 conditions. Of the 4 trials unique to South Africa, 
3 are on HIV/AIDS; of the 19 multinational trials involving 
South Africa, 4 more are on HIV/AIDS. There is no particular 
clustering by condition among the remaining 15 trials in the 
country, and consequently no evidence to support claims that 
South Africa is a unique guinea pig in such trialling.
Implications for policy
Pharmaceutical clinical trials in South Africa involve an R&D 
expenditure of R822 million. This forms part of an overall 
health-related R&D expenditure of R2.088 billion. The bulk 
of R&D in the pharmaceutical industry involves foreign-led 
global phase III clinical trials. Only two phase I clinical trials 
are being undertaken and these are listed as foreign-supported. 
The www.clinicaltrials.gov register does not reveal any South 
African company as the sponsor of a clinical trial. 
The R&D survey shows very low R&D-related capital 
expenditure by business, which is not sufficient for the 
widespread invention and production of active pharmaceutical 
ingredients. The R119 million capital expenditure for R&D 
invested by the industry in 2005/6 originated mostly in one 
company, and is far too small to drive drug discovery. The 
focus of pharmaceutical R&D in South Africa is thus in the area 
of clinical trials, and not discovery.
The health sciences total fulltime researcher availability, 
including doctoral and post-doctoral students, was estimated 
at approximately 3 700 (unpublished data extract for the 
Department of Science and Technology by Centre for Science, 
Technology and Innovation Indicators). This resource, spread 
over all medical research fields, should be seen against the 
resources of a pharma such as AstraZeneca, which employs 
12 000 researchers worldwide.6 South Africa neither has the 
requisite human resources to be internationally competitive in 
pharmaceutical R&D, nor does it invest nearly enough. This is 
in line with findings of the National Economic Development 
and Labour Council,7 which suggest that R&D growth in the 
Table I. Pharmaceutical sector R&D main parameters
04/05 Expenditure 05/06 Expenditure  05/06 Current 05/06 Capital  05/06 Labour Headcount Full-time  
      equivalent
R756 M         R822 M      R474 M       R119 M      R237 M       584     491
Table II. Funding of SA business sector pharmaceutical 
R&D
Sources of funds  Amount (RM)
Business – business (domestic or contracts)        11.0
Foreign sources        420.0
Government – contracts          0.1
Government – grants           0.2
Organisation – own funds      391.0
   Total       822.0
Source: CeSTII Survey Management and Results System internal database
Table III. Clinical trials involving South African sites, by 
phase5 
 I II III IV Total
Global 0 27 113  9 149
SA 1  2    1  0    4
SA + 4 1  9    7  2   19
  Total 2 38 121 11 172
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South African pharmaceutical industry is more likely to be in 
clinical trials than in basic R&D.
However, good prospects exist for increased clinical trials 
activity. There are factors that may attract this, such as well-
established credentials in medical research, high-quality 
personnel, relatively good infrastructure,8 access to a larger 
African market, a relatively drug-naïve population, and a high 
burden of disease.
Policies should therefore be directed towards this end, 
and could include application of new R&D tax incentives, 
co-financing, access to infrastructure, a proactive regulatory 
environment, and better application of immigration regulations 
as a means toward ‘brain gain’ of highly skilled personnel.
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Incidence of nevirapine-associated hepatitis in an antenatal 
clinic
V Black, H Rees 
In April 2004 the South African Department of Health initiated 
comprehensive care for HIV-infected people that included 
the use of antiretroviral therapy (ART) in the public health 
sector.  The first-line regimen consists of two nucleoside 
reverse transcriptase inhibitors, lamivudine and stavudine, 
together with a non-nucleoside reverse transcriptase inhibitor, 
either efavirenz or nevirapine.1 As efavirenz is thought to be a 
teratogen and is classified as a Food and Drug Administration 
(FDA) category D drug, nevirapine is the preferred agent for 
use in pregnant women, for women planning a pregnancy and 
for women at risk of becoming pregnant. Nevirapine is a highly 
effective antiretroviral (ARV) agent when used in combination 
with other appropriate ARVs.2 Nevirapine has two principal 
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Objective. To describe the incidence, clinical presentation 
and management of nevirapine-associated hepatitis among 
antiretroviral-naïve pregnant women treated with nevirapine- 
based antiretroviral therapy at a dedicated antenatal 
antiretroviral clinic.
Methods. Retrospective analysis of pregnant women initiated 
on nevirapine-based highly active antiretroviral therapy at 
a dedicated antenatal antiretroviral clinic between July 2004 
and December 2006.
Results. Three hundred and ninety women were included in 
the analysis. Median age was 29 (interquartile range (IQR) 
26 - 32) years and median pre-treatment CD4 cell counts was 
157 (IQR 104 - 193) cells/µl. Baseline alanine transaminase 
(ALT)  was elevated in 2.8% of women (11/390). After 
initiation of nevirapine-based ART 8% (31/390) experienced 
an ALT elevation. Three of these patients developed clinical 
hepatitis with jaundice (0.8%, 3/390). The mean and median 
time to clinical presentation was 5 weeks. Hepatitis resolved 
following discontinuation of ART. Non-nevirapine regimens 
were initiated following biochemical and symptomatic 
improvement; symptoms did not recur.
Conclusions.  Among pregnant women, nevirapine-containing 
ART has a favourable safety profile, with a low incidence of 
serious hepatic events.
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